Enzoflam

# Enzoflam > **🛑 WARNING: Enzoflam is a combination product (Diclofenac, Paracetamol, Serratiopeptidase). Dosage must address all components.** For this concise review, we focus on the most commonly available formulation and indications, emphasizing anti-inflammatory/analgesic effects. ## Overview - **Classification**: Combination analgesic, non-steroidal anti-inflammatory drug (NSAID), and anti-edema agent. - **Mechanism**: Diclofenac inhibits COX-1 and COX-2 enzymes, reducing prostaglandin synthesis (anti-inflammatory/analgesic). Paracetamol (Acetaminophen) provides central analgesia. Serratiopeptidase is a fibrinolytic enzyme intended to reduce inflammation and edema. ## Primary Indications 1. **Acute Pain Relief** - Mild to moderate pain associated with musculoskeletal injuries. 2. **Inflammation Management** - Reduction of swelling and inflammation in post-operative or traumatic conditions. 3. **Rheumatic Conditions** - Symptomatic relief of pain and inflammation in certain inflammatory joint diseases. ## Adult Dosing ### Standard Dosing (Common Formulation Example: 50mg Diclofenac + 325mg Paracetamol + 15mg Serratiopeptidase) **Acute Pain and Inflammation** - **Dose**: **1 tablet** (based on formulation above) - **Frequency**: Every 8 to 12 hours (TID/BID) - **Route**: Oral - **Duration**: Short-term; usually limited to **5-7 days** due to diclofenac/paracetamol risk. ### Dose Adjustments - **Renal Impairment**: Diclofenac requires caution. CrCl < 30 mL/min: **Avoid use** or reduce diclofenac dose significantly. - **Hepatic Impairment**: Paracetamol/Diclofenac are hepatotoxic. **Contraindicated** in severe impairment. Use lowest dose for shortest duration in mild impairment. - **Elderly Patients**: Start at the **lowest effective dose**. Increased risk of GI bleeding, renal impairment, and CNS effects (diclofenac). **Limit duration.** ## Pediatric Dosing > **⚠️ Safety Note**: Combination products like Enzoflam are **NOT typically recommended** for routine pediatric use due to varied component dosing, lack of specific trials, and complexity in managing three active ingredients concurrently. Consult local guidelines for single-agent NSAIDs. ### Neonates (0-28 days) - **Dose**: **Contraindicated**. - **Special Notes**: Safety and efficacy not established. High risk of adverse effects. ### Infants (1-12 months) - **Dose**: **Contraindicated**. - **Special Notes**: Use single-agent Paracetamol or Ibuprofen if indicated for pain/fever. ### Children (1-12 years) - **Dose**: **Do not use fixed-dose combination**. - **Special Notes**: If using individual components: Diclofenac dosing is complex (often 0.5-2 mg/kg/day divided). Paracetamol dose: **10-15 mg/kg** every 4-6 hours. Never exceed maximum daily limits. ### Adolescents (13-18 years) - **Dose**: Use a single-agent NSAID initially. If combination is required (rarely): may approach adult dosing but adhere strictly to **lowest effective dose**. - **Maximum**: Follow adult established maximum daily limits for Diclofenac (**150 mg/day**) and Paracetamol (typically **3000 mg/day**). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to NSAIDs (aspirin triad, asthma/urticaria following NSAIDs). - **Absolute**: Active peptic ulcer disease or GI bleeding. - **Absolute**: Severe heart failure (NYHA Class II-IV). - **Absolute**: Severe hepatic or renal impairment. - **Relative**: Last trimester of pregnancy (risk of ductus arteriosus closure). ### Common Adverse Effects - **Very Common (>10%)**: Gastrointestinal upset (nausea, dyspepsia). - **Common (1-10%)**: Headache, dizziness, diarrhea, elevated liver enzymes (transient). - **Serious but Rare**: GI perforation/bleeding, acute kidney injury (AKI), severe hepatotoxicity (paracetamol leading to liver failure), serious skin reactions (SJS/TEN). ### Key Drug Interactions - **Warfarin/Anticoagulants**: Increased risk of bleeding due to platelet effect (diclofenac). **Monitor INR closely.** - **Other NSAIDs/Aspirin**: Synergistic GI toxicity risk. **Avoid concomitant use.** - **Diuretics (e.g., Furosemide) & ACE Inhibitors**: Reduced antihypertensive effect; increased risk of **renal failure**. - **Alcohol**: Greatly increased risk of **hepatotoxicity** (paracetamol component). ## Monitoring & Follow-up - **Before Treatment**: Baseline creatinine (Cr), liver function tests (LFTs) if prolonged use or liver risk. Assess cardiovascular risk. - **During Treatment**: Monitor Cr and LFTs periodically (especially after 2 weeks). Monitor blood pressure. - **Clinical Signs**: Watch for black/tarry stools (GI bleed), persistent abdominal pain, unexplained fatigue/jaundice (hepatotoxicity). ## Clinical Pearls - 💡 **Tip 1**: Always use the **lowest effective dose** for the **shortest duration** to minimize GI, renal, and hepatic risks. - 💡 **Tip 2**: For patients with GI risk, consider co-prescribing a Proton Pump Inhibitor (PPI). - 💡 **Tip 3**: Counsel patients to **avoid exceeding the dose** due to the hidden danger of paracetamol overdose when combining with other over-the-counter products. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.